Holen Sie sich die Stockscreener-App
0.9964
1.46%
0.017
Schlusskurs vom Vortag:
$0.9794
Offen:
$0.952
24-Stunden-Volumen:
890.96K
Relative Volume:
0.75
Marktkapitalisierung:
$87.41M
Einnahmen:
$2.24M
Nettoeinkommen (Verlust:
$-136.67M
KGV:
-0.4351
EPS:
-2.29
Netto-Cashflow:
$-102.08M
1W Leistung:
+48.89%
1M Leistung:
+91.10%
6M Leistung:
+67.15%
1J Leistung:
-3.05%
1-Tages-Spanne:
$0.9515
$1.09
1-Wochen-Bereich:
$0.6651
$1.09
52-Wochen-Spanne:
$0.3418
$1.185
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Vergleichen Sie IPSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.00 | 85.60M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.92 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.89 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.77 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.60 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
| 2021-07-13 | Eingeleitet | BofA Securities | Buy |
| 2021-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
What sentiment indicators say about Century Therapeutics Inc. stockJuly 2025 Review & Fast Entry Momentum Alerts - DonanımHaber
Can Century Therapeutics Inc. stock surprise with earnings upsideMarket Weekly Review & Weekly High Momentum Picks - DonanımHaber
Will Century Therapeutics Inc. stock benefit from infrastructure spendingStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Will Century Therapeutics Inc. stock deliver better than expected guidance2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - DonanımHaber
Can Century Therapeutics Inc. stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber
Century Therapeutics adds veteran deal-makers to board as pipeline nears clinic - MSN
Why Century Therapeutics Inc. stock is popular among millennialsRisk Management & Target Return Focused Stock Picks - DonanımHaber
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st
Brent Pfeiffenberger Purchases 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics CEO Brent Pfeiffenberger Acquires 52,000 Shares - TradingView — Track All Markets
Century Therapeutics (IPSC) CEO and director reports 52,000-share buy - Stock Titan
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic - MyChesCo
Century Therapeutics (NASDAQ:IPSC) Trading Up 2.5% – Still a Buy? - Defense World
Century Therapeutics Earnings Notes - Trefis
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics, Inc. Updates on Cell Therapy Developments - TradingView — Track All Markets
IPS Cell-Derived Platelets Market to Rise at 9.6% CAGR Through 2025-2031: Industry and Companies Analysis Featuring Megakaryon, Xueji Shengwu, Renerval, Help, Cynata, Fate, and Century TherapeuticsResearchAndMarkets.com - Markets Financial Content
Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors - MSN
Century Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Century Therapeutics director reports zero beneficial share ownership | IPSC SEC FilingForm 3 - Stock Titan
Fed Meeting: Why Century Therapeutics Inc stock attracts global investorsGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Century Therapeutics appoints two new board members By Investing.com - Investing.com Australia
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy To Board - citybiz
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors - Yahoo Finance
Century Therapeutics appoints two new board members - Investing.com
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - The Manila Times
Century Therapeutics Appoints Dr. Han Lee and Dr. Martin Murphy to Board of Directors - Quiver Quantitative
Century Therapeutics Appoints Accomplished Biotechnology - GlobeNewswire
Officer Russotti Files To Sell 526 Of Century Therapeutics Inc [IPSC] - TradingView — Track All Markets
Century Therapeutics (IPSC) price target decreased by 20.00% to 4.08 - MSN
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Will Century Therapeutics Inc. stock outperform international peersMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
What analysts say about APA Corporation stockMarket Sentiment Report & Enter Your Email to Get Stock Alerts - earlytimes.in
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Century Therapeutics 'moving with urgency' to develop drug for Type 1 diabetes - The Business Journals
There is no way Century Therapeutics Inc (IPSC) can keep these numbers up - Setenews
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
IPSC 2026 special meeting to vote on Nasdaq-driven reverse split - Stock Titan
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What machine learning models say about Century Therapeutics Inc.2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Leerink Partners Reaffirms “Market Perform” Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - Defense World
Take off with Century Therapeutics Inc (IPSC): Get ready for trading - Setenews
What technical signals suggest for Century Therapeutics Inc. stockCPI Data & Accurate Entry and Exit Point Alerts - newser.com
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Century Therapeutics Inc-Aktie (IPSC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Dec 08 '25 |
Sale |
0.53 |
257 |
137 |
404,874 |
| Russotti Gregory | See Remarks |
Dec 08 '25 |
Sale |
0.53 |
526 |
280 |
390,982 |
0.29%
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):